RxDoctor Payments Data

Beth Bash

Nurse Practitioner · Butler, PANPI 1225079973

Payments from drug & device makers

$6,767in general payments, 2019–2025

Across 413 payments — averaging $16.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$857
  • AbbVie$846
  • Lilly USA, LLC$646
  • AstraZeneca$521
  • Pfizer$432
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$6,71299%
  • Education$250%
  • Other$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,767 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$48,695
Medicare patients
118
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$83,986
TrulicityDulaglutide45$56,109
JanuviaSitagliptin Phosphate42$48,988
MounjaroTirzepatide26$25,766
EliquisApixaban34$19,708
OzempicSemaglutide16$19,457
Breo ElliptaFluticasone/Vilanterol33$17,992
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,814
UbrelvyUbrogepant12$13,627
TradjentaLinagliptin18$13,459
XareltoRivaroxaban15$11,890
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$11,443
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,003
FarxigaDapagliflozin Propanediol16$10,788
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$4,331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$225$97,444119 claims
Lilly USA, LLCTrulicity, Mounjaro$646$81,87471 claims
MerckJanuvia$112$48,98842 claims
GSKBreo Ellipta, Trelegy Ellipta, Incruse Ellipta$1,236$37,63666 claims
AstraZenecaBreztri Aerosphere, Farxiga$521$21,79134 claims
PfizerEliquis$432$19,70834 claims
Novo NordiskOzempic$857$19,45716 claims
AbbVieUbrelvy, Synthroid$846$16,70072 claims
Johnson & JohnsonXarelto$29$11,89015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Butler

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →